Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six ...

Johnson & Johnson today announced a new analysis of Phase 3 data which found CAPLYTA® (lumateperone), in combination with an antidepressant, showed significantly greater remission rates in adults with ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under physician oversight.

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation ...

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

Metabolic dysregulation has been implicated in major depressive disorder (MDD), but the causal relationship between plasma ...

Adding a daily fish oil supplement to psychotherapy showed no significant benefit over placebo for kids and teens with ...

Mood symptoms alone do not account for the extent of disability associated with MDD. 12 Cognitive impairment, 1 of the 9 core symptoms of MDD (see Table 1), is significantly associated with impaired ...

Dr. Hans Eriksson, Chief Medical Officer, presented clinical findings from the OLIVE Phase 2b trial, which evaluated BH-200 (nelivaptan) in 338 patients with Major Depressive Disorder (MDD), using a ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...